Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180035/S034

MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

CooperVision, Inc. · Decision date Feb 17, 2026

FDA DECISIONP180035/S034

What did the FDA decide?

FDA records P180035/S034 as a supplement to PMA P180035, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 17, 2026.

FDA approval order statement

introduction of a secondary packaging line within the CooperVision, Inc. facility in West Henrietta, New York
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Feb 17, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P180035/S034
Regulatory pathway
PMA supplement
Product code
QIT
Decision code
OK30
Decision date
Feb 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Daily wear soft contact lens to reduce the progression of myopia.

Product code
QIT
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P180035/S030 · Related supplement

    MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

  2. P180035/S031 · Related supplement

    MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

  3. P180035/S032 · Related supplement

    MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

  4. P180035/S033 · Related supplement

    MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear

  5. P180035/S034 received

    Application receipt date recorded by FDA.

  6. P180035/S034 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P180035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180035

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

CooperVision, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5870 Stoneridge Dr., Suite 1, Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records